Diflucan 150 mg (Fluconazole) and Rilpivirine: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Azole CYP3A inhibition can increase rilpivirine exposure.
Clinical significance and safety
This systemic azole antifungal can increase oral rilpivirine exposure. The label does not require a routine rilpivirine adjustment, but recommends clinical review and monitoring for breakthrough fungal infection; other cardiac-risk medicines should also be checked.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.